Synthes USA Products LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.9Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
314clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Na $166K associated (2023-2025)
- Lcp $96K associated (2023-2025)
- Va-Lcp $78K associated (2023-2025)
- Expert Nail $40K associated (2023-2025)
- Trumatch $13K associated (2023-2025)
- Matrixrib $12K associated (2023-2025)
- Milagro $11K associated (2023-2025)
- Hammerlock $10K associated (2023-2025)
- Zipfix $6,960 associated (2023-2025)
- Tfn-Advance $5,969 associated (2023-2025)
- Matrix $5,269 associated (2023-2025)
- Motoband $2,871 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Sean Nork | Seattle, WA | Orthopaedic Trauma | $188,101.89 |
| Raymond White | Portland, ME | Orthopaedic Trauma | $52,955.57 |
| Sean Grambart | Des Moines, IA | Foot & Ankle Surgery | $39,250.92 |
| Stephen Warner | Houston, TX | Orthopaedic Trauma | $37,128.12 |
| Steve Behrens | New York, NY | Orthopaedic Surgery | $34,295.91 |
| Samir Mehta | Philadelphia, PA | Orthopaedic Surgery | $29,643.37 |
| Matthew Graves | Jackson, MS | Orthopaedic Surgery | $29,619.13 |
| Joshua Blomberg | Neenah, WI | Orthopaedic Trauma | $29,052.85 |
| Scott Bartlett | Philadelphia, PA | Plastic Surgery | $26,200.76 |
| Michael Gardner | Stanford, CA | Orthopaedic Trauma | $23,740.78 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.